Article
Immunology
Qin Zhou, Jiawei Xu, Yan Xu, Shaokun Sun, Jian Chen
Summary: The study found that low ICAM1 expression may be related to immune escape, leading to poor treatment response and a worse prognosis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yanlin Li, Tiantian Wu, Ziluo Peng, Xianyan Tian, Qian Dai, Miao Chen, Jun Zhu, Song Xia, Aiqin Sun, Wannian Yang, Qiong Lin
Summary: ETS1 is highly expressed in breast tumor tissues, specifically associated with tumor metastasis and poor survival in TNBC. Depletion of ETS1 inhibited cell proliferation and migration in TNBC cells by downregulating YAP and its target genes.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Xudong Zhu, Jiawen Bu, Tong Zhu, Yi Jiang
Summary: KK-LC-1 is highly expressed in triple-negative breast cancer and is associated with poor prognosis. Silencing KK-LC-1 can inhibit malignant behaviors of triple-negative breast cancer through the MAL2/MUC1-C/PI3K/AKT/mTOR pathway. The small molecule compound Z839878730 can target KK-LC-1 and kill cancer cells effectively.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Peipei Shan, Feifei Yang, Hongzhao Qi, Yunjie Hu, Sujie Zhu, Zhenqing Sun, Zhe Zhang, Chuanxiao Wang, Caixia Hou, Jie Yu, Lirong Wang, Zhixia Zhou, Peifeng Li, Hua Zhang, Kun Wang
Summary: The study reveals the essential role of MDM2 in TNBC progression, suggesting that targeting the HDAC1-MDM2-MDMX axis with a hydroxamate-based HDAC1 could be a promising therapeutic strategy for TNBC.
Article
Genetics & Heredity
Justine Marsolier, Pacome Prompsy, Adeline Durand, Anne-Marie Lyne, Camille Landragin, Amandine Trouchet, Sabrina Tenreira Bento, Almut Eisele, Sophie Foulon, Lea Baudre, Kevin Grosselin, Mylene Bohec, Sylvain Baulande, Ahmed Dahmani, Laura Sourd, Eric Letouze, Anne-Vincent Salomon, Elisabetta Marangoni, Leila Perie, Celine Vallot
Summary: The persistence of drug-resistant cancer cells is a major clinical challenge, particularly in triple-negative breast cancer. This study reveals that the repressive histone mark H3K27me3 plays a crucial role in regulating cell fate and chemotherapy tolerance in cancer cells. Manipulating H3K27me3 levels effectively enhances the potential of cancer cells to tolerate chemotherapy and delays tumor recurrence. These findings underscore the importance of understanding chromatin landscapes in shaping cancer cell response to initial therapy.
Article
Cell Biology
Anli Yang, Fu Peng, Lewei Zhu, Xing Li, Shunling Ou, Zhongying Huang, Song Wu, Cheng Peng, Peng Liu, Yanan Kong
Summary: Melatonin treatment downregulated FUNDC1 and lnc049808 in TNBC cell lines, which inhibited cell proliferation, invasion, and metastasis. lnc049808 and FUNDC1 acted as competing endogenous RNAs binding to miR-101, indicating a potential therapeutic pathway for TNBC progression inhibition by melatonin.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Weihua Jiang, Xiao-Liang Xing, Chenguang Zhang, Lina Yi, Wenting Xu, Jianghua Ou, Ning Zhu
Summary: The study found that the expression of MET and FASN in TNBC patients is closely related to clinical pathological characteristics and prognosis, with positive expression significantly correlated with lymph node metastasis, pathological TNM, and pathological Stage. The combined use of MET and FASN can better predict the survival condition of patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Alexander S. Roesler, Smriti Malasi, Lori Koslosky, Peter Hartmayer, Tammey J. Naab, Jodi M. Carter, David Zahrieh, David Hillman, Roberto A. Leon-Ferre, Fergus J. Couch, Matthew P. Goetz, Karen S. Anderson, Barbara A. Pockaj, Michael T. Barrett
Summary: We investigated the prevalence, prognostic value, and enrichment by chemotherapy of the PDJ amplicon in TNBC. Our findings demonstrate that the prevalence of PDJ amplicons in TNBC varies extensively and is associated with poor clinical outcomes.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Acharya Balkrishna, Rashmi Mittal, Vedpriya Arya
Summary: This review summarizes the role of miRNA in triple-negative breast cancer, suggesting that miRNA can inhibit metastatic cascade through various mechanisms and may serve as prognostic and metastatic biomarkers.
CURRENT CANCER DRUG TARGETS
(2021)
Article
Biochemistry & Molecular Biology
Lijuan Guo, Wanjun Zhang, Xue Zhang, Jun Wang, Jiaqi Nie, Xiaomeng Jin, Ying Ma, Shi Wang, Xinhong Zhou, Yilei Zhang, Yan Xu, Yoshimasa Tanaka, Jingping Yuan, Xing-Hua Liao, Yiping Gong, Li Su
Summary: In this study, SIPA1 was found to function as a transcription factor that regulates the expression of genes involved in cell growth, differentiation, and response to environmental factors. Importin β1 was identified as an interacting partner of SIPA1 during fibronectin treatment. SIPA1's DNA-binding region (DBR) recognized and bound to a TGAGTCAB motif, and its transcriptional regulation was shown to be necessary for the migration and invasion of triple-negative breast cancer cells.
Article
Multidisciplinary Sciences
Jiahui Xu, Xiaoli Yang, Qiaodan Deng, Cong Yang, Dong Wang, Guojuan Jiang, Xiaohong Yao, Xueyan He, Jiajun Ding, Jiankun Qiang, Juchuanli Tu, Rui Zhang, Qun-Ying Lei, Zhi-min Shao, Xiuwu Bian, Ronggui Hu, Lixing Zhang, Suling Liu
Summary: Enhanced neovasculogenesis, especially vasculogenic mimicry (VM), contributes to the development of triple-negative breast cancer (TNBC). We identified TEM8 as a functional marker for VM-forming BTICs in TNBC, providing a target for the development of effective therapies against TNBC targeting both BTIC self-renewal and neovasculogenesis simultaneously. TEM8 promotes stemness and VM differentiation capacity through a RhoC/ROCK1/SMAD5 axis.
NATURE COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Selase Ativui, Cynthia A. Danquah, Paul Poku Sampene Ossei, Michael Ofori
Summary: This study demonstrated that palmatine has the potential to improve hypoxemia, ameliorate metastasis-associated lung injury, decrease lung MTA1 expression, and increase p53 expression in the treatment of lung metastasis from triple negative breast cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Materials Science, Multidisciplinary
Qingxin Mu, Guanyou Lin, Mike Jeon, Hui Wang, Fei-Chien Chang, Richard A. Revia, John Yu, Miqin Zhang
Summary: This study presents a multifunctional nanoparticle formulation targeting TNBC cells and dendritic cells, inducing tumor apoptosis through multiple mechanisms and significantly inhibiting tumor growth and metastasis while extending survival in a drug-resistant mouse model of TNBC. The promising platform may substantially improve therapeutic efficacy for treating metastatic TNBC.
Review
Oncology
Juan Zhang, Qi Tian, Mi Zhang, Hui Wang, Lei Wu, Jin Yang
Summary: Breast cancer is a common female cancer worldwide, with triple-negative breast cancer being one of the most dangerous subtypes with high mortality and relapse rates. Immunotherapy has become a promising and effective treatment, but not all patients are sensitive to it, highlighting the importance of selecting suitable candidates for immunotherapy. Recent discoveries in immune-related factors of TNBC offer insights into predicting prognosis and response to immunotherapy.
Review
Oncology
Hussein Sabit, Emre Cevik, Huseyin Tombuloglu, Shaimaa Abdel-Ghany, Guzin Tombuloglu, Manel Esteller
Summary: This review elucidates the role of miRNAs in triple negative breast cancer (TNBC), categorizing them based on specific mechanisms in TNBC. The study highlights the importance of accurate diagnosis, prognosis, and treatment approaches for this aggressive subtype of breast cancer, summarizing the most up-to-date findings in miRNA profiling and therapeutic strategies.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Karuna Mittal, Michael S. Toss, Guanhao Wei, Jaspreet Kaur, Da Hoon Choi, Brian D. Melton, Remus M. Osan, Islam M. Miligy, Andrew R. Green, Emiel A. M. Janssen, Havard Soiland, Keerthi Gogineni, Upender Manne, Padmashree Rida, Emad A. Rakha, Ritu Aneja
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Frank A. Vicini, G. Bruce Mann, Chirag Shah, Sheila Weinmann, Michael C. Leo, Pat Whitworth, Rachel Rabinovitch, Mylin A. Torres, Julie A. Margenthaler, David Dabbs, Jess Savala, Steven C. Shivers, Karuna Mittal, Fredrik Warnberg, Troy Bremer
Summary: This study aimed to identify women with DCIS who have a low risk of IBR after BCS and can omit RT, as well as those with elevated IBR risk remaining after BCS plus RT, by evaluating a novel biosignature for a residual risk subtype (RRt). Patients were classified into three risk groups based on the biosignature and DS, and IBR rates were assessed by risk group and treatment. The novel biosignature identified three distinct risk profiles: Low Risk, Elevated Risk, and Residual Risk, highlighting the need for different treatment approaches for each group.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)